

**NC Medicaid  
Outpatient Pharmacy  
Prior Approval Criteria  
Crinone 8% Gel (progesterone)**

**Effective Date: 11/01/2014**

**Amended Date: January 5, 2026**

**Therapeutic Class Code:** G2A

**Therapeutic Class Description:** Progestational Agents

<b>Medication</b>
Crinone 8% Gel (progesterone)

**Eligible Beneficiaries**

NC Medicaid (Medicaid) beneficiaries shall be enrolled on the date of service and may have service restrictions due to their eligibility category that would make them ineligible for this service.

**EPSDT Special Provision: Exception to Policy Limitations for Beneficiaries under 21 Years of Age**

**42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]**

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiaries under 21 years of age **if** the service is **medically necessary health care** to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed clinician). This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his/her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems. Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary's physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary's right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product, or procedure

- a. that is unsafe, ineffective, or experimental/investigational.
- b. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and/or other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider's documentation shows that the requested service is medically necessary "to correct or ameliorate a defect, physical or mental illness, or a condition" [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary's health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

**EPSDT and Prior Approval Requirements**

**NC Medicaid  
Outpatient Pharmacy  
Prior Approval Criteria**

**Effective Date: 11/01/2014**

**Crinone 8% Gel (progesterone)**

**Amended Date: January 5, 2026**

- a. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does **NOT** eliminate the requirement for prior approval.
- b. **IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the *Basic Medicaid Billing Guide*, sections 2 and 6, and on the EPSDT provider page. The Web addresses are specified below.

*NCTracks Provider Claims and Billing Assistance Guide:*

<https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html>

EPSDT provider page: <https://medicaid.ncdhhs.gov/medicaid/get-started/find-programs-and-services-right-you/medicaid-benefit-children-and-adolescents>

**Criteria:**

- Documented ultrasound of transvaginal cervical length (TVCL)  $\leq$  25mm between weeks 17 and 24 of gestation OR
- Diagnosis of secondary amenorrhea in patients who have failed Crinone 4% gel AND
- Crinone 8% is not being used for infertility

**Procedures:**

- Approve for 2 boxes (15 single use applicators per box) per 30 days
- Approve until the end of pregnancy; For secondary amenorrhea: approve for 12 months

**References**

1. Romero R, Niolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the mid trimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. *Am J Obstet Gynecol* 2012;206:124.e1-19
2. Campbell S. Universal Cervical length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. *Ultrasound Obstet Gynecol.* 38 (1), 1-9 (2011)
3. Fonseca, EB. Progesterone and the risk of preterm birth among women with a short cervix. *N Engl J Med* 2007 Aug, 2:357(5): 462-9
4. DeFranco, E.A., et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2007; 30: 697-705

**NC Medicaid  
Outpatient Pharmacy  
Prior Approval Criteria**

**Effective Date: 11/01/2014**

**Crinone 8% Gel (progesterone)**

**Amended Date: January 5, 2026**

5. O'Brien, J.M, et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2009; 34: 653-659
6. Crinone [package insert]. Irvine, CA; Allergan. June 2017.

**NC Medicaid  
Outpatient Pharmacy  
Prior Approval Criteria  
Crinone 8% Gel (progesterone)**

**Effective Date: 11/01/2014**

**Amended Date: January 5, 2026**

**Criteria Change Log**

11/01/2014	Criteria effective date
	Removed GSNs
04/13/2021	Added secondary amenorrhea to document for coverage
01/05/2026	Criteria Reviewed. No Changes